Previous 10 | Next 10 |
2024-05-31 15:00:19 ET More on the markets Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight Hedge funds back at record exposure to Magnificent 7 S&am...
2024-05-31 11:06:15 ET More on Gilead Sciences Gilead's Trodelvy misses primary endpoint in phase 3 bladder cancer trial Gilead Sciences: Seriously Undervalued At Peak Pessimism Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish Unlo...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 8.6% to $0.0384 on volume of 89,961,220 shares Nuburu Inc. (BURU) rose 29.4% to $0.207 on volume of 85,213,370 shares Novo Integrated Sciences Inc. (NVOS) rose 139.5% to $1.08 on volume ...
– Simultaneously Published by the Journal of Clinical Oncology – Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA8500) today (2:45-5:45pm CT) at the 2024 Ame...
2024-05-30 17:06:32 ET More on Gilead Sciences Gilead Sciences: Seriously Undervalued At Peak Pessimism Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows Gilead partner...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC). The TROPiCS-04 study evaluated Trodelvy ® (sacituzumab govitecan-hziy; SG) vs. single-agent chemotherapy (treatme...
2024-05-29 10:47:04 ET CVS Health Corp (CVS) CVS is trading DOWN for the last 4 days, and it at trading at $55.80 with volume of 15,015,387 and a one day change of $-0.18 (-0.31%). CVS Health Corp has a 52-week low of 53.70 and a 52-week high of $83.25. The business's 50-day moving ...
2024-05-28 14:34:16 ET More on G1 Therapeutics G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript G1 Therapeu...
2024-05-28 13:31:54 ET Summary On April 26, Gilead Sciences published financial results for the first quarter of 2024, which were better than I expected. So, total sales of oncology drugs amounted to $789 million, up about 18% yearly thanks to strong sales of Trodelvy. On May ...
2024-05-28 10:23:08 ET More on Gilead Sciences Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors ...
News, Short Squeeze, Breakout and More Instantly...
– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Im...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this trans...